Hemodynamic changes by recombinant erythropoietin therapy in hemodialyzed patients.
Recombinant human erythropoietin therapy was given to 15 patients undergoing long-term hemodialysis with normal cardiac function. None of the patients had hypertension before the erythropoietin therapy and had received no antihypertensive agents. Before and after the erythropoietin therapy M-mode and pulsed Doppler echocardiographic studies, measurements of plasma volume by radioiodinated human serum albumin, and measurements of atrial natriuretic factor were carried out. After 6 weeks of erythropoietin therapy, hematocrit increased from 20.0 to 33.0%. Cardiac output, stroke volume, left ventricular diastolic dimensions, and left ventricular wall stress were all significantly decreased. Total peripheral resistance, interventricular septal thickness, and left ventricular posterior wall thickness were significantly increased. In Doppler echocardiographic studies, the mean velocity of aortic ejection flow and left ventricular acceleration time were decreased. The blood volume derived from plasma volume and hematocrit was not changed, whereas plasma atrial natriuretic factor concentration was significantly decreased. These data suggest that recombinant human erythropoietin administration suppressed the hyperdynamic cardiac state that was required to maintain oxygen delivery to the peripheral tissues in severe uremic anemia.
Satoh
K
K
Department of Medicine, Kitasato University School of Medicine, Kanagawa, Japan.
Masuda
T
T
Ikeda
Y
Y
Kurokawa
S
S
Kamata
K
K
Kikawada
R
R
Takamoto
T
T
Marumo
F
F
D000328:Adult; D000368:Aged; D001794:Blood Pressure; D004452:Echocardiography / Q000379:methods; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006339:Heart Rate; D006439:Hemodynamics; D006801:Humans; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use*; D006435:Renal Dialysis
D011994:Recombinant Proteins; D004921:Erythropoietin